Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 2/20 | 0.47 |
| ▸ | CCKBR | P32239 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871841 | 0.93 | L3MBTL1 (0.47) | SCN9ACTSLL3MBTL1ACE | |
| SCHEMBL4873372 | 0.89 | HDAC4 (0.44) | SCN9ACTSSCTSKACE | |
| SCHEMBL4864001 | 0.88 | SCN9A (0.52) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4868278 | 0.83 | SCN9A (0.53) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL3054407 | 0.81 | SCN9A (0.64) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL3957208 | 0.80 | SCN9A (0.58) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4867141 | 0.79 | SCN9A (0.51) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL7274495 | 0.79 | CTSS (0.60) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4861770 | 0.79 | SCN9A (0.50) | SCN9ACTSSCTSLCTSBCTSK | |
| SCHEMBL4868037 | 0.79 | HRH2 (0.46) | SCN9ACTSLL3MBTL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | claimed |
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | PKD1, DDC, DPYD | SCN9A 1111/4885CTSS 1167/4885CTSL 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.